Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Study Summary

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Conditions

AML (Acute Myeloid Leukemia)Glioma Cholangiocarcinoma Solid Tumor Malignancies

Interventions / Drugs

Olutasidenib CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates

View on ClinicalTrials.gov ↗

Sponsor

RIGL

Rigel Pharmaceuticals

Immunology

D39/100

Study Details

Enrollment16 participants

Primary Completion—

Lead SponsorRigel Pharmaceuticals

Data Retrieved2026-04-11 04:25:58.320527+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.